16 min

Adjuvant radiotherapy versus early salvage radiotherapy in prostate cancer The Lancet Oncology in conversation with

    • Medicine

Paul Sargos (Institut Bergonié, France) discusses the GETUG-AFU 17 trial and Andrew Kneebone (Royal North Shore Hospital and University of Sidney, Australia) the RAVES trial.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Paul Sargos (Institut Bergonié, France) discusses the GETUG-AFU 17 trial and Andrew Kneebone (Royal North Shore Hospital and University of Sidney, Australia) the RAVES trial.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

16 min